A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Linus Sun, MD, PhD
Denali Therapeutics Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centre for Human Drug Research (chdr)
Leiden, South Holland, Netherlands
- Honorhealth
Scottsdale, Arizona, United States
- University of California at San Diego
San Diego, California, United States
- California Pacific Medical Center
San Francisco, California, United States
- Ppd Orlando
Orlando, Florida, United States
- Emory University
Atlanta, Georgia, United States
- Atrium Health Neurosciences Institute
Charlotte, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Aug 2021
- Primary completion
- 15 Dec 2022
- Completion
- 5 Jun 2024
- Last update posted
- 19 Sept 2024
- Registered enrollment
- 29
- Registry id
- NCT05006352
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.